IP Library Granted Patent US 11,117,972
Granted Patent B2
US 11,117,972 · App. 16/295,332 · Granted Sep 14, 2021

Multivalent and multispecific OX40-binding fusion proteins

Inventors: Brendan P. Eckelman (La Jolla, CA); John C. Timmer (La Jolla, CA); Chelsie Hata (La Jolla, CA); Kyle S. Jones (La Jolla, CA); Abrahim Hussain (La Jolla, CA); Amir S. Razai (La Jolla, CA); Bryan Becklund (La Jolla, CA); Rajay Pandit (La Jolla, CA); Mike Kaplan (La Jolla, CA); Lucas Rascon (La Jolla, CA); Quinn Deveraux (La Jolla, CA)
Assignee: Inhibrx, Inc.
C07K16/2878C07K16/2827A61K2039/505C07K2317/24C07K2317/31C07K2317/33C07K2317/35C07K2317/52C07K2317/569C07K2317/75C07K2317/76C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,972
App. No.
16/295,332
Granted
Sep 14, 2021
Kind
B2
Abstract

This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.

Claims (20)

1. An isolated polypeptide that binds human OX40 and comprises at least one VHH that binds to OX40, wherein the at least one VHH that binds to OX40 comprises a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 36, a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 37, and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 42.

2. The isolated polypeptide of claim 1 , wherein the isolated polypeptide is monospecific.

3. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises at least two VHHs, and wherein at least one VHH of the isolated polypeptide binds DR5, GITR, or CD137.

4. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises at least two VHHs, and wherein at least one VHH of the isolated polypeptide binds PDL1.

5. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises at least two VHHs, and wherein at least two VHHs of the isolated polypeptide are operably linked via a linker polypeptide.

6. The isolated polypeptide of claim 5 , wherein the linker polypeptide consists of 5-20 amino acids.

7. The isolated polypeptide of claim 6 , wherein the linker polypeptide is composed predominantly of glycine and serine.

8. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises an immunoglobulin Fc region polypeptide.

9. The isolated polypeptide of claim 8 , wherein the immunoglobulin Fc region polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6.

10. The isolated polypeptide of claim 1 , wherein the at least one VHH that binds to OX40 is a humanized VHH.

11. The isolated polypeptide of claim 1 , wherein the at least one VHH that binds to OX40 comprises an amino acid sequence selected from SEQ ID NOs: 25 and 377-385.

12. The isolated polypeptide of claim 1 , wherein the isolated polypeptide is tetravalent.

13. The isolated polypeptide of claim 12 , wherein the isolated polypeptide is dimeric and each molecule of the dimer comprises the structure: VHH-Linker-VHH-Linker-Hinge-Fc, wherein each VHH is a humanized VHH.

14. The isolated polypeptide of claim 1 , wherein the isolated polypeptide is hexavalent.

15. The isolated polypeptide of claim 14 , wherein the isolated polypeptide is dimeric and each molecule of the dimer comprises the structure: VHH-Linker-VHH-Linker-VHH-Linker-Hinge-Fc, wherein each VHH is a humanized VHH.

16. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 389-394.

17. An isolated nucleic acid that encodes the isolated polypeptide of claim 1 .

18. An isolated vector comprising the nucleic acid of claim 17 .

19. An isolated host cell comprising the nucleic acid of claim 17 .

20. An isolated host cell that expresses the polypeptide of claim 1 .

Assignments (5)
SECURITY INTEREST Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2019
From: RASCON, LUCAS
To: INHIBRX, INC.
Reel/Frame 050265/0685 →
Continuity (3)
Division 15404167 · Jan 11, 2017
Provisional Application 62277027 · Jan 11, 2016
Related Publication 20190263916A1 · Aug 29, 2019
Cited By (1)
US 12,304,961